Praluent is used to help reduce the risk of heart attack and stroke.
Under the restructured agreement, Regeneron will have the sole responsibility for Praluent in the US and record net product sales, while Sanofi will be in charge of the product outside the US and pay a royalty on its net product sales to Regeneron.
As part of the restructuring, Regeneron has also made some revisions to the presentation of its consolidated financial statements, effective Jan. 1, reflecting changes to reimbursements and other payments for products developed and commercialized in joint venture partnerships.
With the implementation of the latest changes, Regeneron will not record any reimbursements for research and development and selling, general and administrative expenses from partners as revenue.
As a result of the accounting changes, the company expects total revenue and operating expenses to be about $300 million for Q1, lower than with the previous accounting treatment.
The company does not expect any impact from the changes to income from operations, income taxes, net income and net income per share.
Shares of Sanofi were down more than 2% and Regeneron was down nearly 1% in Tuesday morning trading.
Price: 500.95, Change: -3.32, Percent Change: -0.66
|Consensus for Zumiez Q2 Earnings Raised but Full Yea...|
|Williams Sonoma's Q2, 2021, 2022 Full Year Earnings ...|
|Analysts' Ratchet Up 2020, 2021 Consensus Estimates ...|
|Q1, 2021, 2022 Earnings Estimates for Advanced Drain...|
|Q2 Projection for Westlake Chemical Increased but 20...|